Pharmacoeconomics of sedation in the ICU

Anesthesiology Clinics

Volumn 29, Issue 4, 2011, Pages 707-720

  Dasta, Joseph F ^a,b,c   Kane Gill, Sandra ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c NONE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cost effectiveness; Costs and cost analysis; Critical care; Critical illness; Economics; Health resources; Intensive care units; Length of stay; Pharmaceuticals

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; LORAZEPAM; MIDAZOLAM; PROPOFOL; REMIFENTANIL; SEDATIVE AGENT;

ARTIFICIAL VENTILATION; BREATHING RATE; COST EFFECTIVENESS ANALYSIS; DELIRIUM; HEALTH CARE COST; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INTENSIVE CARE UNIT; LONG TERM CARE; REVIEW; SEDATION; SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 81055150438     PISSN: 19322275     EISSN: 22103538     Source Type: Journal    
DOI: 10.1016/j.anclin.2011.09.009     Document Type: Review

References (40)

1. Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31(5):1312-1317.
2. Dasta J.F., Kane-Gill S., Durtschi A.J., et al. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008, 23(6):1970-1974.
3. Ng T., Dasta J.F., Feldman D.F., et al. Differences in patients with a primary vs secondary discharge diagnosis of heart failure from a database of 2.5 million admissions: implications for health care policy reform. Congest Heart Fail 2008, 14(4):202-210.
4. Weber R.J., Kane S.L., Oriolo V.A., et al. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 2003, 31(Suppl 1):S17-S24.
5. Dasta J., Kim S.R., McLaughlin T.P., et al. Incremental daily cost of mechanical ventilation in patients receiving treatment in an intensive care unit. Crit Care Med 2005, 33(6):1266-1271.
6. Sessler C.N., Varney K. Patient-focused sedation and analgesia in the ICU. Chest 2008, 133(2):552-565.
7. Shartz M., Young D.W., Siegrist R. The ratio of costs to charges: how good a basis for estimating costs?. Inquiry 1995, 32(4):476-481.
8. Glydmark M. A review of cost studies of intensive care units: problems with the cost concept. Crit Care Med 1995, 23(8):964-972.
9. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update. Circulation 2009, 119(3):480-486.
10. Fraser G., Riker R.R., Prato S., et al. The frequency and cost of patient-initiated device removal in the ICU. Pharmacotherapy 2001, 21(1):1-6.
11. Rudis M.I., Guslits B.J., Peterson E.L., et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996, 24(10):1749-1756.
12. Jenney A.W., Harrington G.A., Russo P.L., et al. Cost of surgical site infections following coronary artery bypass surgery. ANZ J Surg 2001, 71(11):662-664.
13. Martin R.A., Perez A., San Georgio M.A. Psychological adaptation in relatives of critically injured patients admitted to an intensive care unit. Span J Psychol 2005, 8(1):36-44.
14. Nelson J.L., Haas C.E., Habtemariam B., et al. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med 2008, 23(3):184-194.
15. Pandharipande P., Shintani A., Peterson J., et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006, 104(1):21-26.
16. MacLaren R., Sullivan P.W. Economic evaluation of sustained sedation/analgesia in the intensive care unit. Expert Opin Pharmacother 2006, 7(15):2047-2068.
17. Dasta J.F., Durtschi A.J., Kane-Gill S.L. Pharmacoeconomics, in critical care. Fink MP, Abraham E, Vincent JL, et al, editors. Textbook of critical care 2005, 1732-1739. Elsevier Saunders, Philadelphia.
18. Senagore A.J. Pathogenesis and clinical and economic consequences of postoperative ileus. Am J Health Syst Pharm 2007, 64(Suppl 3):S3-S7.
19. Pun B.T., Ely E.W. The importance of diagnosing and managing ICU delirium. Chest 2007, 132(8):624-636.
20. Milbrandt E.B., Seppen S., Harrison P.L., et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med 2004, 32(4):955-962.
21. LeBlanc J., Dasta J.F., Kane-Gill S.L. The role of bispectral index monitoring in the ICU. Ann Pharmacother 2006, 40(3):490-500.
22. Shorr A., Micek S.T., Jackson W.L. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med 2007, 35(5):1257-1262.
23. Quenot J.P., Ladoire S., Devoucoux F., et al. Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia. Crit Care Med 2007, 35(9):2031-2036.
24. Brook A.D., Ahrens T.S., Schaiff R., et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999, 27(12):2609-2615.
25. Devlin J.W., Nasraway S.A. Reversing oversedation in the intensive care unit: the role of pharmacists in energizing guideline efforts and overcoming protocol fatigue. Crit Care Med 2008, 36(2):626-628.
26. Marshalll J., Finn C.A., Theodore A.C. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med 2008, 36:427-433.
27. Wittbrodt E.T. Analysis of pharmacoeconomics of sedation and analgesia. Crit Care Clin 2001, 17(4):1003-1013.
28. Anis A.H., Wang X.H., Leon H., et al. Economic evaluation of propofol for sedation of patients admitted to intensive care units. Anesthesiology 2002, 96(1):196-201.
29. MacLaren R., Sullivan P.W. Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients. Pharmacotherapy 2005, 25(10):1319-1328.
30. Muellejans B., Matthey T., Scholpp J., et al. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomized, open-label, pharmacoeconomic trial. Crit Care 2006, 10:R91.
31. Dasta J.F., Jacobi J., Sesti A., et al. Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis. Pharmacotherapy 2006, 26(6):798-805.
32. Dasta J.F., Kane-Gill S.L., Pencina M., et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010, 38:497-503.
33. Panharipande P.P., Pun B.T., Herr D., et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. JAMA 2007, 298(22):2644-2653.
34. Cox C.E., Reed S.D., Govert J.A., et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med 2008, 36(3):706-714.
35. Al MJ., Hakkaart L., Tan S.S., et al. Cost-consequence analysis of remifentanil-based analog-sedation vs conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Crit Care 2010, 14:R195.
36. Riker R.R., Shehabi Y., Bokesch P.M., et al. Dexmedetomidine vs. midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009, 305(5):489-499.
37. Jacobi J., Fraser G.L., Coursin D.B., et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002, 30(1):119-141.
38. Egerod I. Cultural changes in ICU sedation management. Qual Health Res 2009, 19:687-696.
39. Rozendaal F.W., Spronk P.E., Snellen F.F., et al. Remifentanil-propofol analog-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. Intens Care Med 2009, 35:291-298.
40. American Thoracic Society Understanding costs and cost-effectiveness in critical care. Am J Respir Crit Care Med 2002, 165(2):540-550.